Corporate ActionJun 24, 2026, 05:21 PM
Definium Therapeutics Raises $758M Net in Upsized Public Offering
AI Summary
Definium Therapeutics, Inc. announced the pricing and full exercise of an upsized underwritten public offering, expecting to raise approximately $758 million in net proceeds. The company sold 20,588,236 common shares at $34.00 per share, with underwriters fully exercising their option for an additional 3,088,235 shares. Proceeds will fund research and development of product candidates, preparation for potential commercialization of DT120 ODT, and general corporate purposes. The offering is expected to close on June 25, 2026.
Key Highlights
- Raised approximately $758 million in net proceeds from an upsized public offering.
- Sold 20,588,236 common shares at a public offering price of $34.00 per share.
- Underwriters fully exercised their option to purchase an additional 3,088,235 common shares.
- Gross proceeds from the offering are expected to be approximately $805 million.
- Net proceeds will be used for research and development of product candidates, including DT120 ODT.
- Funds also allocated for preparation activities for potential commercialization and general corporate purposes.
- Company directors and executive officers agreed to a 60-day lock-up period on common shares.
- The offering is expected to close on June 25, 2026.
Price Impact
More from DFTX